CRH to buy Arcosa in $8.5 billion deal
CRH (NYSE:CRH) signed a definitive agreement to purchase competitor Arcosa for $150 per share in cash.
CRH (NYSE:CRH) signed a definitive agreement to purchase competitor Arcosa for $150 per share in cash.
Fervo Energy (NASDAQ:FRVO) reported a first-quarter net loss of $31.8 million while funding multiple utility-scale geothermal facilities.
Galmed Pharmaceuticals (NASDAQ:GLMD) closed its Colospan acquisition, gaining a device tested on 97 patients.
Definium Therapeutics (NASDAQ:DFTX) stated its depression drug trial succeeded, showing a key 8.1-point improvement over a placebo.
AbbVie (NYSE:ABBV) executed an agreement to acquire Apogee Therapeutics (NASDAQ:APGE) for $135.11 per share in cash, totaling approximately $10.9 billion.
HawkEye 360 (NYSE:HAWK) achieved record first-quarter 2026 revenue of $49.8 million due to strong global demand.
Merck (NYSE:MRK) announced positive topline results from its Phase 3 study evaluating tulisokibart for active ulcerative colitis.
Tokyo's Metropolitan Police Department arrested Hu Xiaowei, 44, a Cypriot national also known as Hu Shi, on suspicion of submitting false residency information to Japanese authorities, according to The Asahi Shimbun.
Ennis (NYSE:EBF) reported a 1.4% increase in first-quarter revenue to $98.6 million for the period ended May 31, 2026.
Petróleo Brasileiro, also known as Petrobas (NYSE:PBR) approved the final investment decision for a $1.2 billion biorefining project to produce renewable fuels.
GARANTA JÁ SEU GRAFA EDGE
Sign up free to unlock this feature
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas